Dr. Stone on MRD in Hematologic Malignancies

Richard M. Stone, MD
Published: Thursday, Oct 26, 2017



Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses minimal residual disease (MRD) in hematologic malignancies.

According to Stone, it makes sense to use MRD in acute lymphoblastic leukemia (ALL) where there are more data and antibody therapies. However, in other subtypes, physicians are not sure whether the patient should have a transplant or an antibody approach.

There are 2 US trials attempting to determine if an antibody therapy used earlier in the course of the disease that reduces MRD will result in better outcomes.
 


Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses minimal residual disease (MRD) in hematologic malignancies.

According to Stone, it makes sense to use MRD in acute lymphoblastic leukemia (ALL) where there are more data and antibody therapies. However, in other subtypes, physicians are not sure whether the patient should have a transplant or an antibody approach.

There are 2 US trials attempting to determine if an antibody therapy used earlier in the course of the disease that reduces MRD will result in better outcomes.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted TherapiesMar 31, 20181.5
Publication Bottom Border
Border Publication
x